JP2019501363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501363A5 JP2019501363A5 JP2018516113A JP2018516113A JP2019501363A5 JP 2019501363 A5 JP2019501363 A5 JP 2019501363A5 JP 2018516113 A JP2018516113 A JP 2018516113A JP 2018516113 A JP2018516113 A JP 2018516113A JP 2019501363 A5 JP2019501363 A5 JP 2019501363A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine
- protein
- reactive probe
- moiety
- reactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 27
- 235000018102 proteins Nutrition 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 18
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 14
- 235000018417 cysteine Nutrition 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 13
- 150000003384 small molecules Chemical group 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- -1 N-hydroxysuccinimide (NHS) ester Chemical class 0.000 claims 3
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 claims 2
- 150000001345 alkine derivatives Chemical group 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 102000034573 Channels Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims 1
- 108010006519 Molecular Chaperones Proteins 0.000 claims 1
- 108091005764 adaptor proteins Proteins 0.000 claims 1
- 102000035181 adaptor proteins Human genes 0.000 claims 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 125000005262 alkoxyamine group Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 210000004292 cytoskeleton Anatomy 0.000 claims 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims 1
- 125000005179 haloacetyl group Chemical group 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- RDBMUARQWLPMNW-UHFFFAOYSA-N phosphanylmethanol Chemical compound OCP RDBMUARQWLPMNW-UHFFFAOYSA-N 0.000 claims 1
- 238000000575 proteomic method Methods 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- GWIKYPMLNBTJHR-UHFFFAOYSA-M thiosulfonate group Chemical group S(=S)(=O)[O-] GWIKYPMLNBTJHR-UHFFFAOYSA-M 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562244881P | 2015-10-22 | 2015-10-22 | |
| US62/244,881 | 2015-10-22 | ||
| US201662345710P | 2016-06-03 | 2016-06-03 | |
| US62/345,710 | 2016-06-03 | ||
| PCT/US2016/058308 WO2017070611A1 (en) | 2015-10-22 | 2016-10-21 | Cysteine reactive probes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501363A JP2019501363A (ja) | 2019-01-17 |
| JP2019501363A5 true JP2019501363A5 (cg-RX-API-DMAC7.html) | 2020-01-30 |
| JP6953400B2 JP6953400B2 (ja) | 2021-10-27 |
Family
ID=58558160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516113A Active JP6953400B2 (ja) | 2015-10-22 | 2016-10-21 | システイン反応性プローブとその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10670605B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3365686A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6953400B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3001847A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017070611A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015023724A1 (en) | 2013-08-13 | 2015-02-19 | The Scripps Research Institute | Cysteine-reactive ligand discovery in proteomes |
| EP3365686A4 (en) | 2015-10-22 | 2019-03-27 | The Scripps Research Institute | REACTIVE CYSTEINSONS AND USES THEREOF |
| CA3024523A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US20190216893A1 (en) * | 2016-06-03 | 2019-07-18 | The Scripps Research Institute | Compositions and methods of modulating immune response |
| AU2018211066B2 (en) | 2017-01-18 | 2024-03-21 | The Scripps Research Institute | Photoreactive ligands and uses thereof |
| WO2018144869A1 (en) * | 2017-02-03 | 2018-08-09 | The Regents Of The University Of California | Compositons and methods for modulating uba5 |
| KR20190126074A (ko) * | 2017-02-03 | 2019-11-08 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 레티쿨론 4를 억제하기 위한 조성물 및 방법 |
| WO2018144871A1 (en) * | 2017-02-03 | 2018-08-09 | The Regents Of The University Of California | Compositions and methods for modulating ppp2r1a |
| US20200239530A1 (en) * | 2017-09-27 | 2020-07-30 | Vividion Therapeutics, Inc. | Compounds and methods of modulating protein degradation |
| EP3688472A4 (en) * | 2017-09-27 | 2021-06-23 | The Scripps Research Institute | Conjugated proteins and uses thereof |
| EP3694528A4 (en) | 2017-10-13 | 2021-07-28 | The Regents of the University of California | MTORC1 MODULATORS |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| UA125802C2 (uk) | 2017-11-15 | 2022-06-08 | Міраті Терапьютікс, Інк. | Інгібітори kras g12c |
| CN111698986B (zh) * | 2017-12-11 | 2023-02-03 | 广州君赫生物科技有限公司 | 双硫仑的新应用 |
| EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3111977A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2020214336A2 (en) | 2019-03-21 | 2020-10-22 | University Of Virginia Patent Foundation | Sulfur-heterocycle exchange chemistry and uses thereof |
| EP4010459A4 (en) * | 2019-08-05 | 2023-09-06 | Bridgene Biosciences, Inc. | METHOD FOR DISCOVERING PROTEOME-WIDE COVALENT LIGANDS AND ASSOCIATED COMPOSITIONS |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
| CA3157710A1 (en) * | 2019-10-15 | 2021-04-22 | Jnana Therapeutics Inc. | Reactive affinity probe-interaction discovery platform |
| WO2021076703A1 (en) * | 2019-10-16 | 2021-04-22 | Vividion Therapeutics, Inc. | Compounds and methods for modulating immune-related proteins |
| KR20220103943A (ko) * | 2019-10-16 | 2022-07-25 | 더 스크립스 리서치 인스티튜트 | 일차 인간 면역 세포에서 친전자체-시스테인 상호작용의 활성-가이드 맵 |
| CN111063389B (zh) * | 2019-12-04 | 2021-10-29 | 浙江工业大学 | 一种基于深度卷积神经网络的配体绑定残基预测方法 |
| US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
| BR112023004569A2 (pt) | 2020-09-11 | 2023-04-04 | Mirati Therapeutics Inc | Formas cristalinas de um inibidor de kras g12c |
| CN112255396A (zh) * | 2020-10-15 | 2021-01-22 | 南开大学 | 一种测量小分子药物抑制蛋白核酸互作的单分子力学方法 |
| MX2023007084A (es) | 2020-12-15 | 2023-08-30 | Mirati Therapeutics Inc | Inhibidores de pan-kras de azaquinazolina. |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022240966A1 (en) * | 2021-05-11 | 2022-11-17 | Opna Immuno-Oncology Sa | Compounds and methods for yap/tead modulation and indications therefor |
| WO2023092133A1 (en) * | 2021-11-22 | 2023-05-25 | The Scripps Research Institute | Stereoselective covalent ligands for oncogenic and immunological proteins |
| WO2024059575A2 (en) * | 2022-09-12 | 2024-03-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition, device, system, and methods for detecting environmental toxicants |
| WO2024073486A2 (en) * | 2022-09-28 | 2024-04-04 | The General Hospital Corporation | Probes and methods to identify ligandable fatty acylation sites for therapeutic target identification |
| CN116790698B (zh) * | 2023-06-21 | 2024-06-18 | 南京大学 | 基于氧化脱羧酶的硫醛合成方法及其应用 |
| WO2025182683A1 (ja) * | 2024-02-29 | 2025-09-04 | 国立大学法人 東京大学 | タンパク質の活性／反応性部位の、活性／反応性の評価方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6344330B1 (en) | 1998-03-27 | 2002-02-05 | The Regents Of The University Of California | Pharmacophore recombination for the identification of small molecule drug lead compounds |
| AU5477100A (en) * | 1999-06-10 | 2001-01-02 | Pharmacia & Upjohn Company | Caspase-8 crystals, models and methods |
| DK1337853T3 (da) * | 2000-11-21 | 2009-05-04 | Sunesis Pharmaceuticals Inc | Udvidet forankringstiltag til hurtig identifikation af ligander |
| WO2005118833A2 (en) | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak) |
| US7935479B2 (en) | 2004-07-19 | 2011-05-03 | Cell Biosciences, Inc. | Methods and devices for analyte detection |
| US8314215B2 (en) * | 2006-08-04 | 2012-11-20 | The Board Of Trustees Of The Leland Stanford Junior University | Mild chemically cleavable linker system |
| EP2060563A4 (en) * | 2006-09-08 | 2010-12-22 | Dainippon Sumitomo Pharma Co | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE |
| JP2010505868A (ja) | 2006-10-02 | 2010-02-25 | ザ スクリプス リサーチ インスティチュート | エーテル脂質シグナル伝達経路を制御する酵素 |
| CN101219219B (zh) * | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
| EP1947193A1 (en) | 2007-01-17 | 2008-07-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening method for anti-diabetic compounds |
| WO2008109997A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Procaspase 8-mediated disease targeting |
| AP2010005377A0 (en) * | 2008-02-26 | 2010-08-31 | Univ Muenchen L Maximilians | Beta-lactones as antibacterial agents. |
| WO2013192364A1 (en) * | 2012-06-22 | 2013-12-27 | The University Of Vermont And State Agricultural College | Treatments of oxidative stress conditions |
| US20140357512A1 (en) | 2013-06-03 | 2014-12-04 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase (hdac) biomarkers in multiple myeloma |
| WO2015023724A1 (en) * | 2013-08-13 | 2015-02-19 | The Scripps Research Institute | Cysteine-reactive ligand discovery in proteomes |
| WO2016029037A1 (en) | 2014-08-21 | 2016-02-25 | Srx Cardio, Llc | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
| EP3365686A4 (en) * | 2015-10-22 | 2019-03-27 | The Scripps Research Institute | REACTIVE CYSTEINSONS AND USES THEREOF |
| AU2018211066B2 (en) | 2017-01-18 | 2024-03-21 | The Scripps Research Institute | Photoreactive ligands and uses thereof |
-
2016
- 2016-10-21 EP EP16858391.2A patent/EP3365686A4/en not_active Withdrawn
- 2016-10-21 JP JP2018516113A patent/JP6953400B2/ja active Active
- 2016-10-21 US US15/331,745 patent/US10670605B2/en active Active
- 2016-10-21 WO PCT/US2016/058308 patent/WO2017070611A1/en not_active Ceased
- 2016-10-21 CA CA3001847A patent/CA3001847A1/en active Pending
-
2020
- 2020-06-02 US US16/890,966 patent/US20200292555A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501363A5 (cg-RX-API-DMAC7.html) | ||
| Mertins et al. | Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry | |
| Ostasiewicz et al. | Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry | |
| Bartoschik et al. | Near-native, site-specific and purification-free protein labeling for quantitative protein interaction analysis by MicroScale Thermophoresis | |
| Humphery‐Smith et al. | Proteome research: complementarity and limitations with respect to the RNA and DNA worlds | |
| Eaton | Protein thiol oxidation in health and disease: techniques for measuring disulfides and related modifications in complex protein mixtures | |
| Nikolovska-Coleska | Studying protein-protein interactions using surface plasmon resonance | |
| Elschenbroich et al. | Peptide separations by on-line MudPIT compared to isoelectric focusing in an off-gel format: application to a membrane-enriched fraction from C2C12 mouse skeletal muscle cells | |
| JP2011504596A (ja) | サンプル中の分析物を定量測定する際に使用するための内部標準および方法 | |
| Honoré et al. | Functional genomics studied by proteomics | |
| Billakanti et al. | Simultaneous, quantitative detection of five whey proteins in multiple samples by surface plasmon resonance | |
| Haragan et al. | Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry | |
| ATE554106T1 (de) | Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung | |
| Stigter et al. | Coupling surface-plasmon resonance and mass spectrometry to quantify and to identify ligands | |
| JP2006517788A5 (cg-RX-API-DMAC7.html) | ||
| Salimi-Moosavi et al. | Rapid affinity measurement of protein–protein interactions in a microfluidic platform | |
| Campion et al. | Protein quantitation and analysis of purity | |
| Castellanos‐Serra et al. | Detection of biomolecules in electrophoresis gels with salts of imidazole and zinc II: a decade of research | |
| Xu et al. | On‐plate enrichment of glycopeptides by using boronic acid functionalized gold‐coated Si wafer | |
| Haulenbeek et al. | Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance | |
| García-Descalzo et al. | Gel electrophoresis of proteins | |
| JP2005513507A5 (cg-RX-API-DMAC7.html) | ||
| Houfani et al. | Review of the real and sometimes hidden costs in proteomics experimental workflows | |
| EP1589341A2 (en) | Method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixtures | |
| Haab et al. | High-throughput studies of protein glycoforms using antibody–lectin sandwich arrays |